Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nurexone Biologic Inc (NRX.VN)

Nurexone Biologic Inc (NRX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Nurexone Biologic Inc 1 Adelaide St. East Suite 801 Toronto ON M5C 2V9 CAN

https://www.nurexone.com

Description:

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.

Key Statistics

Overview:

Market Capitalization, $K 53,133
Shares Outstanding, K 70,844
Annual Sales, $ 0 K
Annual Net Income, $ -3,639 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,325 K

Growth:

1-Year Return 154.24%
3-Year Return 0.00%
5-Year Return 0.00%

Per-Share Information:

Most Recent Earnings -0.02 on 08/27/24
Next Earnings Date 11/22/24 [--]
Earnings Per Share ttm -0.08
EPS Growth vs. Prev Year -7.06%
Dividend Payout Ratio 0.00%

NRX.VN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -253.66%
Return-on-Assets % -183.92%
Profit Margin % 0.00%
Debt/Equity 0.01
Price/Sales N/A
Price/Book 14.76
Book Value/Share 0.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar